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Abstract

THE EFFECT OF SAHA ON THE EXPRESSION OF GENES IN WILD TYPE AND
HDAC2 KNOCKOUT MOUSE MODELS AND ITS POTENTIAL USE AS TREATMENT
FOR SCHIZOPHRENIA
Maryum Khalid Ijaz, M.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science in Physiology & Biophysics at Virginia Commonwealth University.
Virginia Commonwealth University, 2017
Javier González-Maeso, PhD, Department of Physiology and Biophysics

The symptoms of schizophrenia have been categorized into three subsets
including positive, negative, and cognitive symptoms. Although atypical antipsychotic
use has shown promising reduction in positive and negative symptoms of
schizophrenia, such as hallucination, delusions and flat affect, the cognitive subset of
symptoms remains and has an adverse impact on those affected. Chronic treatment
with the atypical/secondary antipsychotic clozapine is one example that has ameliorated
hallucinations and delusions but results in cognitive memory deficits. When chronically
given in conjunction with the HDAC inhibitor, SAHA, the cognitive memory deficits of
mouse models decline. HDAC2KO mice were bred and used in chronic treatments with
either vehicle or SAHA and compared to WT mice, in order to analyze whether
differential gene expression was occurring in an HDAC2 dependent manner. The
expression of various genes involved in brain function were evaluated using RT-qPCR
to determine potential differential regulation. The results showed differential expression
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of the following genes: Abhd16a, Gbf1, Itch, and Ube2g1. These genes are all involved
in various neuronal functions.
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Chapter 1: Introduction
1. Schizophrenia
According to the National Institute of Mental Health, schizophrenia is a “chronic and
severe mental disorder that affects how a person thinks, feels, and behaves”.
Individuals with the disorder may seem that they have completely lost touch with
reality. Symptoms typically begin between ages 16 and 30 and in some rare cases,
the disorder can manifest in children as well.
1.1. Clinical features of schizophrenia
Symptoms of schizophrenia are typically categorized into three subsets including
positive symptoms, negative symptoms, and cognitive symptoms (11, 13).
1.1.1. Positive symptoms
Positive symptoms are the presence of beliefs, behaviors, and sensations
that would otherwise not occur normally. These symptoms include
disturbances of thought processes, delusions, and hallucinations (11).
1.1.2. Negative symptoms
Negative symptoms refer to the lack of normal behaviors that are otherwise
present in healthy individuals. These include differences in feelings,
movements, and behavior (11).
1.1.3. Cognitive symptoms
Cognitive symptoms refer to problems such as disorganized thoughts,
difficulty understanding, poor concentration and/or memory, or difficulty
expressing thoughts, feelings, and behaviors (11).
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Figure 1. Demographics of Schizophrenia (Reprinted from: National Institute of
Mental Health)
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1.2. Treatment of Schizophrenia
1.2.1. First generation/Primary antipsychotics
Some examples of commonly used primary or first generation
antipsychotic medications include chlorpromazine, fluphenazine,
thioridazine, and haloperidol. These primary antipsychotics generally treat
positive symptoms successfully, but have limited efficacy for the other two
subsets of symptoms (11). Another negative result of these primary
antipsychotics are their extrapyramidal side effects. Extrapyramidal side
effects are commonly categorized as dystonia, dyskinesia, parkinsonism,
and akathisia. Dystonia is described as abnormality of voluntary muscle
tone or an abnormal degree of fixity associated with sustained muscular
contraction. Similarly, dyskinesia describes impairment or the abnormality
of voluntary movement. Parkinsonism refers to movement abnormalities
usually associated with Parkinson’s disease such as tremor, slow
movement, or impaired speech. Akathisia is another movement disorder
categorized by an inner feeling of restlessness and compulsion to be in
constant motion (21).
1.2.2. Secondary/atypical antipsychotics - Atypical antipsychotics or secondary
antipsychotic drugs include clozapine and risperidone. These drugs block
both 5-HT2A (serotonin) receptors as well as D2 (dopamine) receptors.
Clozapine is commonly used because of its effective treatment of negative
symptoms. However, in many cases cognitive symptoms persist and may
even be heightened (11).
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Figure 2. Chart of symptom subsets associated with schizophrenia as defined by the
NIMH.
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1.3 Epigenetics & Chromatin Remodeling
The definition of epigenetics has evolved and now refers to changes across the
genome that regulate gene transcription without modification of the underlying genome
sequence. Epigenetic changes such as histone modifications such as DNA methylation,
acetylation, and deacetylation are potentially heritable. However, the new focus of
epigenetics is the effect it has on drug treatment and factors that may play in brain
function (3, 8, 28, 29).
In eukaryotic cells, DNA is packaged into a nucleoprotein complex defined as
chromatin. The basic unit of chromatin is a nucleosome, each of which contains 147
base pairs of DNA wrapped twice around an octamer of core histone proteins, including
H2A, H2B, H3, and H4. Histones are proteins that have a globular domain and aminoterminal tail. Chromatin manifests in open and closed structural states. In the open
state, the DNA wrapped around histones becomes unwound and is accessible to
transcriptional machinery. Conversely, histones in the closed state are tightly wound
with DNA, which cannot be transcribed. (8). Histone acetylation results in the open form
of chromatin (euchromatin), while histone deacetylation has the opposite effect and
suppresses DNA transcription (18, 23).
There are four classes of histone deacetylases (HDACs), referred to as Class I - IV.
Each class includes different subsets of HDACs. The focus of this study is HDAC2,
which is a Class I HDAC. Class I HDACs, specifically HDAC1 and HDAC2, are believed
to be responsible for most changes in histone acetylation. The activity of HDACs are
regulated by binding of corepressors and post-translational modifications (5, 7, 23).
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Figure 3. Pictorial depiction of the epigenetic mechanisms underlying histone
acetylation and deacetylation
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Figure 4: Schematic model of improved antipsychotic drug action by HDAC2
inhibition (10)

A. Activation of 5-HT2A by the endogenous neurotransmitter serotonin represses HDAC2
promoter activity, B. Atypical antipsychotic drugs reverse the 5-HT2A-dependent repression of
HDAC2, an effect that is associated with increased HDAC2 binding and repressive histone
modifications at the promoter regions of synaptic plasticity genes, C. Inhibition of HDAC2 by
vorinostat prevents these atypical antipsychotic drug-dependent repressive histone
modifications, which improves the therapeutic efficacy.
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HDACs are expressed differently in various cell types, including neurons,
oligodendrocytes, and astrocytes. However, HDACs have been shown to be expressed
primarily in neurons (8, 9).

1.4 Therapeutic potential of HDAC inhibitors
Chronic administration of atypical antipsychotics, such as clozapine and
risperidone, have been shown to downregulate the gene that encodes the
metabotropic glutamate 2 receptor (mGlu2) via histone deacetylation. Chromatin
immunoprecipitation assays have shown that this deacetylation results from HDAC2
binding to the promoter region of the mGlu2 gene thereby decreasing the levels of
histone 3 acetylation, an epigenetic modification that is normally pro-transcriptive
(11).
The mechanism by which this change occurs begins with a decrease in histone
acetylation at the promoter region of the 5HT2A gene caused by clozapine. This
ultimately leads to increased HDAC2 expression and the subsequent binding of
HDAC2 at the mGlu2 promoter. The net effect of this process is decreased
expression of mGlu2. The significance of this finding was further explored using
mouse models. Mice that were virally induced to over express HDAC2 in the frontal
cortex, thereby decreasing mGlu2 transcription, showed an increase in psychosislike behavior.
In the same study, researchers investigated the effect of the HDAC inhibitor,
suberoylanilide hydroxamic acid (SAHA), also known as vorinostat. SAHA was
injected into mouse prefrontal cortexes, resulting in an increase in mGlu2 and
mGlu3 expression. When SAHA was administered chronically along with clozapine,
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Figure 5. Structure of SAHA/vorinostat.
http://www.reagentsdirect.com/index.php/small-molecules/small-molecules1/saha/saha-vorinostat.html
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SAHA blocked the downregulating effect of clozapine on mGlu2. Furthermore, it
enhanced the ability of clozapine to ameliorate schizophrenia-like symptoms
induced by administration of the hallucinogen DOI (1-(2,5-dimethoxy-4-iodophenyl)2-aminopropane) or another psychotomimetic drug, MK-801. For these reasons,
HDAC inhibitors are potentially promising as an adjunctive therapy in the treatment
of schizophrenia (11, 12).
2 Previous work in the Maeso Lab
Previous work in the Maeso lab included screening for genes differentially
expressed in mouse prefrontal cortex models following administration SAHA (20
mg/kg) or saline for 21 days. Two groups of mice with three independent biological
replicates per group were used for the microarray study, totaling 6 microarrays. Mice
were sacrificed one day after the last injection. All animals were handled, treated,
and sacrificed at the same time and under the same conditions. RNA and array
processing was also performed at the same time. RNA was extracted from the
mouse frontal cortex using the RNeasy lipid tissue mini kit (Qiagen).
Labeling and hybridization of the samples to Mouse Gene 1.0 ST expression
chip (Affymetrix) were performed by the Mount Sinai Microarray Shared Resource
Facility using standard methodology. Data quality control was performed using the
Affymetrix Expression Console software. Areas under the Receiver Operating
Characteristic curve (ROC) discriminate between positive control probesets and
negative control probesets (pos.vs.neg.auc). All samples were found to be of very
high quality, with pos.vs.neg.auc metric &gt; 0.89 (0.5 being no better than chance
and 1.0 being perfect distinction), and no outlier was detected. Probe set
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summarization, background correction and normalization were then carried out in
the same software using default settings. Normalized data were analyzed in
MultiExperiment Viewer software and differential gene list was generated using the
Significance Analysis of Microarrays algorithm; Cutoff was chosen so that the false
discovery rate does not exceed 12%. As a result, we obtained a final list of 284
probe sets, corresponding to 124 RefSeq genes. Pathway enrichment analysis was
performed using the Ingenuity Pathway Analysis, with a score threshold (an
adjusted Fisher Exact p-value) of 0.05 (Supplementary Fig. 19). The microarray
data discussed in this paper have been deposited in NCBI’s Gene Expression
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo). The data analysis criteria used
for our study are recommended by the MicroArray Quality Control project, and these
criteria have been validated to provide a high degree of intersite reproducibility and
inter- and intraplatform reproducibility.
Microarray analysis showed that animals receiving SAHA treatment had
remarkedly increased gene expression when compared with controls (Figure 6).
Because the method of microarray analysis is not as accurate and can result in false
positives. Because the method of microarray analysis is not as accurate and can
result in false positives, various genes were chosen to replicate the experiment
using RT-qPCR to determine whether in fact there was differential expression
(Table 1).
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Figure 6: Microarray Heatmap
Analysis of gene expression after chronic SAHA. Heat map shows
differentially expressed genes in frontal cortex of mice chronically (21 days) treated with
SAHA (20 mg/kg) versus control (three mice per group). Mice were sacrificed one day
after the last injection.
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Table 1: Table of genes
Gene
Lpar2

•

Ankrd9

•

Efnb1

•

S100Z

•

•
Aqp1

•

Abhd16a

•

Eif5

•

Gbf1

•

Itch

•

Ssr3

•

Ube2g1

•

Homer1

•

Function
Lysophosphatidic acids (LPAs) are bioactive lipids that function as
lipid-signaling molecules of different chain lengths and
phosphorylation and are expressed by a wide array of immune
cells (20).
involved in mediating protein-protein interactions in a variety of
different families of proteins (NCBI). It is also involved in various
cell fxns including intracellular adaptor, trafficking, transcription,
signal transduction, and stress response (Wang et al., n.d.).
The protein that is encoded by this gene may play role in cell
adhesion as well as the function and development or even the
maintenance of the nervous system (NCBI).
S100 proteins have regulatory effects on a number of different cell
types such as microglia, neutrophils, lymphocytes, neurons,
astrocytes, schwann cells, and more.
Therefore they participate in both innate and adaptive immune
responses, tissue development and repair, cell migration, and
tumor cell invasion (12).
encodes a functioning water channel protein that permits passive
transfer of water osmotically (NCBI).
Abhydrolase domain containing 15A is included in a cluster of
genes localized for tumor necrosis factor alpha and beta. The
protein this gene encodes is thought to be associated with
immunity as this gene is within the human major histocompatibility
complex class III region (NCBI).
eukaryotic translation initiation factor promotes hydrolysis of GTP
to allow joining of 60S ribosomal subunit with 40S subunit resulting
in the functional 80S ribosomal initiation complex, which is then
active (NCBI)
Golgi brefeldin A resistant guanine nucleotide exchange factor 1 is
involved in regulating proteins to membranes by mediating the
GDP to GTP exchange. It also plays a role in vesicular trafficking
when in the golgi apparatus and is a host factor for viral replication
(NCBI).
Itch E3 ubiquitin protein ligase plays a role in cellular processes
such as erythroid and lymphoid cell differentiation and further
regulates immune responses (NCBI).
The signal sequence receptor is a membrane receptor that
translocates proteins across the ER membrane (NCBI).
Proteins with ubiquitin are important for targeting abnormal
proteins for degradation (NCBI).
Homer is a scaffolding protein that regulates mGluR signaling.
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Hdac1

•

Hdac2

•

Hdac5

•

Long variants of this protein link mGluR and its mediators by their
EVH1 domains. The shorter variants are unable to provide this
linkage and act as a negative protein, disrupting the crosslink
action via mGlur-Homer signaling.
Histone deacetylase 1 encodes a protein that interacts with
retinoblastoma tumor-suppressor protein and controls cell
proliferation and differentiation. This results in a regulation on cell
growth and apoptosis (NCBI).
Histone deacetylase 2 is part of a family of HDACs that
deacetylate lysine residues at the N-terminal regions of core
histones. The protein this gene encodes forms transcriptional
repressor complexes via association with different proteins (NCBI).
The protein encoded by histone deacetylase 5 is part of class II
HDACs and functions to repress transcription when it is tethered to
a promoter (NCBI).

21	
  

Table 2: Table of primers
Homer1 Forward

AGCAGAAGGAAGGCTTGACT

Homer1 Reverse

CACGGTACGGCCAATAACTA

Hdac5 Forward

ACTCCTCTGCACAGCATCC

Hdac5 Reverse

CTGGGGCTACCTCCACCT

Hdac1 Forward

GGCACCAAGAGGAAAGTCTG

Hdac1 Reverse

CAAATTGTGAGTCATGCGGA

Hdac2 Forward

CATGGCGTACAGTCAAGGAG

Hdac2 Reverse

TCATCCGGATTCTATGAGGC

Abhd16a Forward

GCAGCATCTCAACCTCAACA

Abhd16a Reverse

GGTGGTGATGATCTCGTCCT

Gbf1 Forward

CCCAGAGATACCCTCAGAAATGG

Gbf1 Reverse

TCTTGGGCAGGACTCAGTTTG

Eif5 Forward

AGGAAGAAGATGAAGACGAAAATATTG

Eif5 Reverse

TGTTGTCAGACTTCACAGTTTCAACT

Itch Forward

CATCGAAAAAGTTGGCAAAGAA

Itch Reverse

GGTCCAGGCGGTTAAAACAA

Ssr3 Forward

AGGATTTCAGCCGCAACCT

Ssr3 Reverse

CGCGTTCCCGAAGAACAG

Ube2g1 Forward

CCGGCCTCCTAAAATGAAATT

Ube2g1 Reverse

GCAAACATCACCATTTTTATCAACA

Aqp1 Forward

CTAGTGGGTCTGCCCGTGTAA

Aqp1 Reverse

GGAGACTGGAGGACCGAAATAA
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Ankrd9 Forward

CCTGGCAGTGCGAGATCAG

Ankrd9 Reverse

GCTTCGCTGGCACGTATGT

Efnb1 Forward

TGTGTCGCACCCGCACTA

Efnb1 Reverse

GGGTGTCACAGCATTTGGATCT

Lpar2 Forward

GGGCCAGTGCTACTACAACGA

Lpar2 Reverse

AGCTCCTTGCCGCTGTTATTAT

S100z Forward

CGCATCTTCCACCGGTACTC

S100z Reverse

CCCCCTTGTTGAGCTTGAAC
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Chapter 2: Materials and Methods
2.1 Wildtype and HDAC2 Conditional Knockout Mice
Treatment mice included wildtypes of the strain C57BL/6 (Taconic) and HDAC2
conditional knockout mice. Animals were housed with a 12h light/dark cycle and were
provided with access to food and water. Pups were weaned from their mothers after 21
days and were then housed in cages of 3-5 mice. All mice used were 6-8 weeks of age
at the time of treatment and male.
Hdac2 KO mice were obtained from The Jackson Laboratory (stock number:
022625). Heterozygous Hdac2 +/− mice were intercrossed to generate Hdac2−/− mice
on a C57BL/6 background. Homozygosity of the Hdac2-null allele resulted in either
embryonic lethality or partial lethality during the first few days postnatal as a result of
proliferation defects and impaired development (data not shown). These findings are
consistent with some but not all of the prior descriptions of global Hdac2 gene deletion.
Based on this, we therefore used CaMKIIα-Cre transgenic mice on a C57BL/6
background, in which Cre recombinase is efficiently expressed in combination with
conditional loss of function of Hdac2 alleles. In mice, CaMKIIα is expressed postnatally
in forebrain glutamatergic pyramidal neurons, beginning 10–14 d after birth. To delete
HDAC2 function specifically in forebrain glutamatergic pyramidal neurons, we bred
homozygous Hdac2loxP/loxP mice to the CaMKIIα-Cre transgenic line. In contrast to
the global deletion of HDAC2, Hdac2loxP/loxP:CaMKIIα-Cre (Hdac2- cKO) mice were
viable and did not display any gross histological or developmental abnormality (data not
shown). Hdac2loxP/loxP:CaMKIIα-Cre mice were born at near expected Mendelian
ratios (data not shown. Genomic DNA was isolated from ears for genotyping by PCR
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Figure 7: Flow chart of overall procedure
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Figure 8: Strategy for deleting forebrain pyramidal HDAC2 function (h). Western blots
showed decreased HDAC2 protein levels in the frontal cortex, but not cerebellum, of
Hdac2-cKO compared to control littermates (n = 4–6 mice per experimental condition) (l,
m). (10)
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analysis. The primer sequences used were as follows: Hdac2loxP/loxP: Hdac2 wt
allele forward	
  (5′-GCACAGGCTACTACTGT GTAGTCC-3′), Hdac2loxP mutant allele:
forward (5′GTCCCTCGA CCTGCAGGAATTC-3′), Hdac2loxP mutant allele reverse (5′CCACCACTGACATGTACCCAAC-3′); CaMKII-Cre, transgene forward (5′GCGGTCTGGCAGTAAAAACTATC-3′), transgene reverse
(5′GTGAAACAGCATTGCTGTCACTT-3′); internal positive control forward (5′
CTAGGCCACAGAATTGAAAGATCT-3′), internal positive control reverse (5′
GTAGGTGGAAATTCTAGCATCATCC-3′).
2.2 Chronic treatment with saline or SAHA
To test the effect of chronic SAHA treatment on gene expression, both wildtype
mice and HDAC2KO mice were injected (i.p.) once a day for 21 days with SAHA
(20mg/kg; obtained from Cayman Chemical). SAHA was suspended in a minimal
amount of DMSO and brought up to volume with saline on the day of each injection.
Control mice were injected chronically with vehicle (saline). On the day after the last
injection, the mice were sacrificed via cervical dislocation, and the prefrontal cortices
were dissected and stored at –80°C until ready for mRNA isolation.
2.3 Tissue Homogenization & mRNA isolation
The brain tissue was purified using TRIZOL reagent (1 mL per sample) as the
lysis buffer and further isolated via the RNAeasy lipid kit (Qiagen). The brain tissue was
sheared using an 18-gauge needle attached to a 5-ml syringe. Isolated mRNA was
measured using the Nanodrop 1000 software (Thermo Fisher).
RNA ISOLATION PROTOCOL
NOTES
De-contaminate the work area, all work tools, and their surfaces of RNase using 70% EtOH
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followed by RNaseZap. Lay out absorbency paper.
Exclusively use filter-tips.
Chill centrifuge to 4°C.
Get a bucket of ice.
MATERIALS
• RNaseZap
• 70% EtOH
• benchtop absorbency paper
• RNeasy Lipid Tissue mini kit
• 1.5 ml microfuge tubes
• 18-gauge needles
• 5-ml syringes
• RNase-free DNase kit (Qiagen)
• DEPC-treated water
• Kim wipes
PROCEDURE
Tissue Homogenization & RNA Isolation
1. Retrieve brain tissue and place on ice.
2. Add 1 ml QIAzol reagent per sample.
3. Homogenize tissue using an 18-gauge needle attached to a 5-ml syringe. Shear
tissue upwards of 30 times until no more tissue chunks can be seen.
a. Never recap the needle. Dispose of used syringes in sharps container.
4. Transfer to pre-labeled 1.5 microfuge tubes.
5. In the fume hood (which has been de-contaminated with RNaseZAP), add 200 µl
chloroform, secure the cap, vigorously shake for 15 secs, and incubate at room
temperature for 3 mins.
6. Centrifuge at 12,000g for 15 mins at 4°C.
7. While waiting, prepare DNase I incubation mix. For each sample, add 10 µl DNase I
stock solution to 70 µl Buffer RDD. Mix by gently inverting the tube.
a. RDD is supplied with the RNase-Free DNase kit.
b. DNase I is sensitive to physical denaturation, so mixing should only be carried
out by gently inverting the tube. Never vortex.
8. Transfer the upper, aqueous phase to a new 1.5 ml microfuge tube.
a. Do not transfer any interphase solids.
9. Add 1 volume (about 500 µl) of 70% ethanol, and mix thoroughly by vortexing. Do not
centrifuge.
10. Transfer up to 700 µl of the sample to an RNeasy Mini spin column placed in a 2 ml
collection tube. Centrifuge for 15 secs at 8,000g at room temperature. Discard the
flow-through. Repeat until all sample has been applied to the column.
11. Wash the membrane with 350 µl Buffer RW1 and centrifuge for 15 secs at 8,000g
(10,000 rpm). Discard the flow-through.
12. Add 80 µl DNase I incubation mix (from Step 7) directly to the RNeasy spin column
membrane, and incubate at room temperature for 15 min.
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13. Wash with 350 µl Buffer RW1, and centrifuge for 15 secs at 8,000g. Discard the flowthrough.
14. Wash with 500 µl Buffer RPE, and centrifuge for 15 secs at 8,000g. Discard the flowthrough and replace collection tube.
15. Wash with 500 µl Buffer RPE, centrifuge for 3 min at max speed to dry column.
a. Any carryover EtOH will interfere with downstream assays.
16. Carefully remove spin column from the collection tube so column does not contact the
flow-through.
17. Place the spin column in a new, pre-labeled 1.5 ml collection tube. Add 30 µl RNasefree water (provided in kit) directly to the spin column and incubate at room
temperature for 2 mins. Elute by centrifuging for 1 min at 8,000g.
a. To increase yield, repeat previous step using 20 µl of RNase-free water.
18. Place purified RNA on ice. Measure concentration and purity by NanoDrop.

2.4 Reverse Transcription Reaction
Each sample of the same treatment condition was normalized to the lowest
amount of mRNA obtained via the nanodrop software to ensure that the same amount
of mRNA was to be compared between samples. The RT reaction was carried out using
oligo dt, DTT, and dNTPs, followed by a master mix of 5x buffer, Superscript III, and
RNAse out.
2.5 RT-qPCR
cDNA obtained from the reverse transcription reaction was diluted to a 1:40
dilution for the RT-qPCR reaction. The QuantFlex Studio 6 machine was used to carry
out qPCR for a total of 10 uL including 4uL of cDNA, 1 uL of primer, and 5 uL
PowerUp™ SYBR™ Green Master Mix (Thermo Fisher Scientific, Catalog
number: A25777) per reaction well. 384 Well plates were used. In Real-Time qPCR,
a fluorescent reporter molecule is utilized to monitor the progression of the reaction. For
this study, SYBR green was used as the reporter molecule (Figure 7), which allows the
quantification of the template to be based on the fluorescence signal during the
exponential phase of amplification. As each cycle of amplification is carried out, there
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will be an increase in fluorescence intensity, which is proportional to the increase in
concentration of the amplicon.
A method of confirmation to verify specific amplification calls for analysis of the
melt curve. Each reaction was carried out in quadruplicates, meaning there were 4 wells
with the same conditions of cDNA, SYBR green, and primer. The melt curve should
show a single homogenous peak, which would indicate specific amplification. We first
tested the primers to ensure specific amplification by examining the melt curves. After
ensuring that each primer provided a homogenous peak, indicative of specific
amplification, we went on to test the primers on the wildtype and HDAC2 KO samples in
the experiment.
The amplification plot is graphically depicted as fluorescence vs cycle number.
The threshold cycle (Ct) value shows the threshold fluorescence level. Once the plot
crosses this threshold level, the subsequent Ct values can be correlated to the starting
concentration of the sample. (Figure 8).
2.6 Statistical Methods
Ct Medians obtained from RT-qPCR were processed to determine mRNA level
fold change. Significance was tested using a two-tailed t-test (GraphPad PRISM).
Values are shown in Tables 3.1 and 3.2 for wildtypes and conditional Hdac2 KO mice,
respectively.
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Figure 9: Pictorial depiction of SYBR green binding to the amplicon during RTqPCR
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Figure 10: Pictorial description of RT-qPCR amplification plot

35	
  

36	
  

Figure 11: Pictorial depiction of Melt Curve to confirm specific amplification
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Chapter 3: Results
The results are graph representations of a two-tailed t-test conducted by the
PRISM software. Upon analysis, it was found that in wildtypes treated with SAHA vs
vehicle, the genes, ITCH and UBE2G1, were downregulated when treated with SAHA
(Figure 12 D,E). The genes ABHD16A and GBF1 were both upregulated upon
treatment with SAHA in wildtype mice (Figure 12, AB). HDAC2 was significantly
downregulated in wildtype mice treated with SAHA as compared to vehicle (Figure 14,
C).
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TABLE 3.1: TWO-TAILED T-TEST COMPARING QUANTITATIVE EXPRESSION
OF GENES IN WILD TYPE MICE TREATED WITH VEHICLE VS SAHA
GENE

Vehicle treated mice

N

SAHA treated mice

ABHD16A

1.000 ± 0.08611

12 1.322 ± 0.08362

12

0.0137 *

ANKRD9

1.000 ± 0.4725

12 2.888 ± 0.8591

12

0.0672

AQP1

1.000 ± 0.2758

12 1.071 ± 0.1724

12

0.8302

EFNB1

1.000 ± 0.2012

12 0.9913 ± 0.06505

12

0.9675

EIF5

1.000 ± 0.04188

12 0.8799 ± 0.1456

12

0.4452

GBF1

1.000 ± 0.06942

12 1.319 ± 0.1291

12

0.0403

HDAC1

1.000 ± 0.1093

12 0.8623 ± 0.09276

12

0.3470

HDAC2

1.000 ± 0.1148

12 0.6699 ± 0.05243

12

0.0158 *

HDAC5

1.000 ± 0.1371

12 1.043 ± 0.1291

12

0.8224

HOMER1

1.000 ± 0.07692

12 1.195 ± 0.1431

12

0.2429

ITCH

1.000 ± 0.05122

12 0.5699 ± 0.1277

12

0.0040

LPAR2

1.000 ± 0.1155

12 1.130 ± 0.1101

12

0.4258

S100Z

1.000 ± 0.1862

12 1.181 ± 0.1818

12

0.4943

SSR3

1.000 ± 0.3114

12 0.6778 ± 0.1556

12

0.3612

UBE2G1

1.000 ± 0.05237

12 0.7999 ± 0.06986

12

0.0319

Data are shown as mean ± SEM. *p<0.05. Student’s t-test.

N

P value

*

*

*
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TABLE 3.2: TWO-TAILED T-TEST COMPARING QUANTITATIVE EXPRESSION
OF GENES IN HDAC2 KNOCKOUT MICE TREATED WITH VEHICLE VS SAHA
GENE

Vehicle treated mice

N

SAHA treated mice

ABHD16A

1.000 ± 0.1940

6 1.080 ± 0.1791

6

0.7686

ANKRD9

1.000 ± 0.2901

6 1.107 ± 0.09678

6

0.7329

AQP1

1.000 ± 0.3560

6 0.6106 ± 0.04504

6

0.3034

EFNB1

1.000 ± 0.1765

6 1.325 ± 0.3082

6

0.3816

EIF5

1.000 ± 0.2382

6 0.8960 ± 0.1188

6

0.7042

GBF1

1.000 ± 0.1797

6 1.210 ± 0.2726

6

0.5344

HDAC1

1.000 ± 0.07734

6 1.067 ± 0.1578

6

0.7094

HDAC2

1.000 ± 0.1959

6 2.014 ± 0.8279

6

0.2608

HDAC5

1.000 ± 0.1329

6 3.972 ± 2.455

6

0.2546

HOMER1

1.000 ± 0.1217

6 1.156 ± 0.3353

6

0.6717

ITCH

1.000 ± 0.04153

6 1.193 ± 0.1855

6

0.3339

LPAR2

1.000 ± 0.2486

6 0.8205 ± 0.1457

6

0.5473

S100Z

1.000 ± 0.4103

6 0.9759 ± 0.2474

6

0.9609

SSR3

1.000 ± 0.1564

6 1.325 ± 0.2614

6

0.3116

TBKBP1

1.000 ± 0.2087

6 2.356 ± 1.239

6

0.3057

UBE2G1

1.000 ± 0.09328

6 1.343 ± 0.1317

6

0.0598

Data are shown as mean ± SEM. Student’s t-test.

N

P value
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Figure 12: Differential expression of genes was identified by RT-qPCR in wildtypes
and HDAC2 KO mice treated with vehicle vs SAHA. Increased gene expression of
ABHD16A (A) and GBF1 (B) in wildtype mice treated with SAHA. Decreased
expression of ITCH (C) and UBE2G1 (D) in wildtype mice treated with SAHA.
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Figure 13: A trend to increased gene expression of ANKRD9 in wildtype mice
treated with SAHA but not in HDAC2 KO mice
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Figure 14: Significant decrease in expression of HDAC2 when wildtype mice were
chronically treated with HDAC inhibitor, SAHA.
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Chapter 4: Discussion
4.1 Implications of this study
The results show the therapeutic potential of SAHA as it is implicated in some genes
having neurological functioning. Both ITCH and UBE2G1 showed downregulation when
treated with SAHA in wildtypes, but not KO mice. Similarly, both ABHD16A and GBF1
showed upregulation in SAHA treated wildtypes, but not KO mice. There was significant
decreased expression of HDAC2 in wildtype mice treated with the HDAC inhibitor,
SAHA but not HDAC5 or HDAC1. This provides support that these genes are
differentially expressed in an HDAC2 dependent manner. The genes that were deemed
insignificant by RT-qPCR that showed upregulation when tested by microarray analysis
could be for a number of reasons. The experiments conducted at Mt. Sinai previously
were produced in the year 2010. Although the same strain, sex, and age of mice were
used in the experiments conducted at VCU, there easily may be individualized
differences from sample to sample. Of the genes that previously showed differential
expression via microarray analysis ANKRD9 (p<0.0672) showed an upward trend in
wildtypes treated with SAHA when compared to vehicle. However, a two-tailed t-test
deemed the results insignificant for this gene. Further experiments would need to be
carried out to assess whether other genes may possibly be significantly affected.
4.2 Future directions
Future goals stemming from this study include screening more of the target
genes differentially expressed from the microarray analysis. Further, recreating the
experiment with a higher sample size of wildtype mice and HDAC2KO mice would be
required. It would be worth researching sex differences between male and female mice

48	
  

as the work conducted so far has been done exclusively using male mouse models.
Additionally, treating two separate cohorts in conjunction with clozapine and SAHA
respectively may shed more insight into which exact genes overlap in terms of
differential regulation between both treatment types.
Of the genes expressed, UBE2G1 encodes a protein that is a ubiquitin and is
important for targeting abnormal genes for degradation. A study showed that
olanzapine, another second generation antipsychotic, upregulated the expression of
various genes including several ubiquitin-conjugating enzymes, including UBE2G1 (16).
The study did not test the effect of clozapine on UBE2G1 levels. It would be worth
analyzing the expression of this gene in models treated with clozapine, especially
because this gene was down-regulated in SAHA treatment.
Furthermore, the gene ITCH, has been implicated as a regulator for various
neurodevelopmental and neurodegenerative disorders. The protein, ITCH, catalyzes the
degradation of multiple substrates via autophagy and results in regulating molecular
pathways in the brain such as synaptogenesis, synaptic connections, and axon and
dendritic branching.
Golgi brefeldin A resistant guanine nucleotide exchange factor 1 (GBF1) is involved
in regulated proteins to membranes via GDP and GTP exchange. GBF1 typically
functions as a transport between the endoplasmic reticulum and golgi apparatus and
further recruits other GEFs, such as BIG1 and BIG2 to the trans-golgi network (TGN). A
study showed that treatment of neurons with an inhibitor of BIG1 resulted in a significant
decrease in GABAA receptors at the neuronal surface of bovine brain. This suggests
the important function of theses GEFs in trafficking GABAA receptors to the cell surface.
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Mutations in BIG2 have been previously reported to hinder neural progenitor
proliferation and migration in the human cerebral cortex (14). Due to these findings, it
would be worth while to test previous samples to examine whether the expression of
BIG1 and BIG2 also change along with GBF1.
ABHD16A is the primary brain phosphatidylserine hydrolase, which generates
ABHD12. Mutations in ABHD12 are involved in human causes of the neurodegenerative
disorder PHARC (polyneuropathy, hearing loss, ataxia, retinosis pigmentosa, and
cataract) (15, 19). Because of this implication of ABHD16A’s involvement in another
neurodegenerative disorder, it further warrants study in relation to schizophrenia.
Ankrd9, the gene that had an upward trend, is involved in lipid metabolism. More
experiments would need to be carried out to see if that metabolism has any correlation
to the brain, a lipid heavy organ (Wang).
A recent finding implicated epigenetic dysfunction associated with schizophrenia. A
study analyzed postmortem brains from patients diagnosed with schizophrenia and
found these samples were deficient in an extracellular matrix protein, reelin, which
contains several sites for DNA methylation. HDACs increase the expression of this
protein, supporting that the regulation of this protein is under epigenetic control (1).
The gene encoding the protein SMARCA2, a part of the SWI/SNF chromatinremodeling complex has been associated with schizophrenia in genome-wideassociation studies. Polymorphisms in this gene produce a change in gene expression
or the amino acid sequence (2).
It is reported that histone acetylation increases neuronal activity and may sustain
changes in gene expression associated with synaptic plasticity and memory. In mouse
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models of Alzheimer’s disease associated cognitive impairment and neurodegeneration,
HDAC2 levels were increased in both the hippocampus and prefrontal cortex. This
upregulation of HDAC2 corresponded with greater binding of HDAC2 to synaptophysin
and Bdnf, genes associated with synaptic plasticity and learning (6).
Acetylation in the prefrontal cortex region was studied in vitro and in mouse models treated
with either vehicle, Cpd-60, or SAHA, both of which are HDAC inhibitors. Both of these HDAC
inhibitors increased acetylation in the prefrontal cortex by 1.5-2.0 fold, supporting that both of
these suppress HDAC activity in the brain following administration (Schroeder)

Dr. Gonzalez-Maeso is in collaboration with a brain bank in Spain, which has
samples of post mortem human brain of control subjects, untreated schizophrenics, and
treated schizophrenics. Although, we do not have access to samples treated with
SAHA, it would be worthwhile to look at the expression of these specific genes in
subjects treated with atypical antipsychotics to see if they are expressed in the opposite
direction as what we have found in mouse brain models treated with SAHA.
Furthermore, Dr. Gonzalez-Maeso, is in collaboration with VCU School of Medicine
for an ongoing clinical study. Currently, they are in the stage of recruiting patients
diagnosed with schizophrenia who are taking atypical antipsychotic medications. These
patients will receive either SAHA or placebo. To look at the expression of various genes
that have been implicated as differentially expressed in mouse models, an option would
be to test the peripheral blood tissue of these patients for those specific genes post
treatment with SAHA.
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